← Back to Analyst Consensus 
SABS Buy
SAB Biotherapeutics, Inc.
Current Price —
Implied Upside —
Analysts 17
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 0 reiterations from 0 firms
Next Earnings
Nov 11, 2026 (16 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Jun 24, 2026 | Barclays | initiate | — → Overweight | — | 53% |
| Jun 17, 2026 | Chardan Capital | maintain | Buy → Buy | — | 47% |
| Jun 15, 2026 | Leerink Partners | maintain | Outperform → Outperform | — | 50% |
| Jun 15, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| May 22, 2026 | Citigroup | initiate | — → Buy | — | 54% |
| May 20, 2026 | Jefferies | initiate | — → Buy | — | 52% |
| May 12, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| May 11, 2026 | Rodman & Renshaw | reiterate | Buy → Buy | — | 40% |
| Apr 2, 2026 | Rodman & Renshaw | initiate | — → Buy | — | 40% |
| Mar 11, 2026 | Chardan Capital | maintain | Buy → Buy | — | 47% |
| Mar 10, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| Jan 7, 2026 | UBS | initiate | — → Buy | $7 | 54% |
| Dec 19, 2025 | Guggenheim | initiate | — → Buy | $15 | 52% |
| Dec 18, 2025 | Chardan Capital | maintain | Buy → Buy | $12 | 47% |
| Nov 17, 2025 | Chardan Capital | maintain | Buy → Buy | $12 | 47% |
| Sep 19, 2025 | Chardan Capital | maintain | Buy → Buy | $12 | 47% |
| Sep 17, 2025 | Leerink Partners | initiate | — → Outperform | $7 | 50% |
| Aug 8, 2025 | Chardan Capital | maintain | Buy → Buy | $12 | 47% |
| Jul 22, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $9 | 44% |
| May 15, 2025 | Chardan Capital | maintain | Buy → Buy | $20 | 47% |
| Apr 1, 2025 | Chardan Capital | maintain | Buy → Buy | $20 | 47% |
| Apr 1, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $6 | 44% |
| Jan 29, 2025 | Chardan Capital | maintain | Buy → Buy | $25 | 47% |
| Jan 29, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $6 | 44% |
| Nov 7, 2024 | Chardan Capital | maintain | Buy → Buy | $25 | 47% |
| Oct 9, 2024 | Craig-Hallum | initiate | — → Buy | $11 | 54% |
| Sep 12, 2024 | Oppenheimer | reiterate | Outperform → Outperform | $12 | 52% |
| Sep 9, 2024 | Chardan Capital | maintain | Buy → Buy | $25 | 47% |
| Aug 28, 2024 | Oppenheimer | initiate | — → Outperform | $12 | 52% |
| Aug 12, 2024 | Chardan Capital | maintain | Buy → Buy | $25 | 47% |
| Aug 12, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $6 | 44% |
| Jun 7, 2024 | Brookline Capital | initiate | — → Buy | $8 | 38% |
| May 21, 2024 | Chardan Capital | maintain | Buy → Buy | $25 | 47% |
| May 21, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $6 | 44% |
| Apr 16, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $6 | 44% |
| Apr 16, 2024 | Chardan Capital | maintain | Buy → Buy | $25 | 47% |
| Apr 2, 2024 | Chardan Capital | maintain | Buy → Buy | $25 | 47% |
| Apr 2, 2024 | HC Wainwright & Co. | maintain | Buy → Buy | $6 | 44% |
| Jan 8, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $10 | 44% |
Price Target Trend
Apr 21, 2026 Oct 26, 2026
EPS Estimates
+1y —
+1q —
0y —
0q —
Cross-Platform Signals
No cross-platform signals in the last 90 days